NextCure, Inc. (NXTC): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
NextCure, Inc. (NXTC) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 nxtc-20260618xex10d1.htm EX-10.1 Exhibit 10.1 NEXTCURE, INC. AMENDED AND RESTATED 2019 OMNIBUS INCENTIVE PLAN TABLE OF CONTENTS Page 1. PURPOSE 1 2. DEFINITIONS 1 3. ADMINISTRATION OF THE PLAN 9 3.1 Committee . 9 3.1.1 Powers and Authoritie
How this was made
The 30-second read
Why it matters
This type of disclosure typically matters most when it includes specific executive/director changes or material compensation terms; the provided text is dominated by plan document language rather than new, decision-grade specifics.
Market read
Governance and incentive-plan updates are disclosed, but the excerpt does not show the specific personnel/compensation details that would likely drive a tradable catalyst.
What to watch
Traders should verify the missing 8-K exhibit details for the identities of departing/elected directors and the exact compensatory terms, which are not present in the provided excerpt.
Background
The filing is an SEC Form 8-K (Item 5.02 and 5.07) tied to board/officer changes and compensatory arrangements under NextCure’s amended and restated 2019 omnibus incentive plan.
Ticker impact
NextCure filed an 8-K for director/officer departures and elections, plus compensatory arrangements under its incentive plan.
Low likelihood of a large immediate move from this filing alone; any impact would depend on the specific individuals and terms not shown in the excerpt.
The excerpt confirms the 8-K items and includes the incentive plan document text, but does not provide the specific departure/election details or the actual compensation terms that would drive trading decisions.
Market effects
Minimal; this is company-specific governance/compensation disclosure rather than a sector catalyst.
None indicated.
None indicated.
Counterpoint
If the omitted sections include a meaningful executive departure or new appointment, the market reaction could be larger than the plan boilerplate suggests.
Key entities
- companyNextCure, Inc.
Subject of the SEC 8-K covering director/officer changes and compensatory arrangements.
